Antiangiogenic Therapy in Gastroesophageal Cancer

Zhaohui Jin; Harry H. Yoon

doi:10.1016/j.hoc.2017.01.008

Antiangiogenic Therapy in Gastroesophageal Cancer

Zhaohui Jin, Harry H. Yoon

Medical Oncology

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti–human epidermal growth factor receptor 2 therapy.

Original language	English (US)
Pages (from-to)	499-510
Number of pages	12
Journal	Hematology/Oncology Clinics of North America
Volume	31
Issue number	3
DOIs	https://doi.org/10.1016/j.hoc.2017.01.008
State	Published - Jun 2017

Keywords

Angiogenesis
Checkpoint inhibitor
Esophageal cancer
Gastric cancer
Immunotherapy

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2017.01.008

Cite this

@article{0d82719e7d634ffcb2a8647e68ae36e0,

title = "Antiangiogenic Therapy in Gastroesophageal Cancer",

abstract = "Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-na{\"i}ve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti–human epidermal growth factor receptor 2 therapy.",

keywords = "Angiogenesis, Checkpoint inhibitor, Esophageal cancer, Gastric cancer, Immunotherapy",

author = "Zhaohui Jin and Yoon, {Harry H.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = jun,

doi = "10.1016/j.hoc.2017.01.008",

language = "English (US)",

volume = "31",

pages = "499--510",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Antiangiogenic Therapy in Gastroesophageal Cancer

AU - Jin, Zhaohui

AU - Yoon, Harry H.

PY - 2017/6

Y1 - 2017/6

N2 - Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti–human epidermal growth factor receptor 2 therapy.

AB - Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus. Promising ongoing clinical investigations include the combination of antiangiogenesis therapy with immune checkpoint inhibition and anti–human epidermal growth factor receptor 2 therapy.

KW - Angiogenesis

KW - Checkpoint inhibitor

KW - Esophageal cancer

KW - Gastric cancer

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85015790682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015790682&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2017.01.008

DO - 10.1016/j.hoc.2017.01.008

M3 - Review article

C2 - 28501090

AN - SCOPUS:85015790682

SN - 0889-8588

VL - 31

SP - 499

EP - 510

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 3

ER -

Antiangiogenic Therapy in Gastroesophageal Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this